Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274261 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®
A Phase 3 study, sponsored by Premier Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,565
- Enrollment target
NCT00274261 is a Phase 3 study that has completed, run by Premier Research. The registered enrollment target is 1,565 participants.
The verdict
NCT00274261, a Phase 3 study, has completed, sponsored by Premier Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,565 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. In addition, there is an opportunity for subjects to continue with study treatment for up to twelve months (365 days) and twelve cycles of treatment upon completion of the first six months of treatment.
Interventions
- DRUG C31G
- DRUG nonoxynol-9 (N-9)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,565 participants |
| Start Date | 2004-06 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274261
The ClinicalTrials.gov registry entry for NCT00274261 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Premier Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which C31G is the first listed.
NCT00274261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274261 about?
NCT00274261 is a clinical study titled "Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®". This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. In addition, there is an opportunity for subjects to...
What is the current status of trial NCT00274261?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,565 participants. The study started on 2004-06. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00274261?
The interventions under investigation include: C31G (DRUG), nonoxynol-9 (N-9) (DRUG).
Who is sponsoring clinical trial NCT00274261?
This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.